Revance Therapeutics was founded in 2002 and is headquartered in Newark, US

Revance Therapeutics has an office in Newark

Newark, US (HQ)

7555 Gateway Blvd

Revance Therapeutics's revenue was reported to be $75 k in Q1, 2017

USD

## Revenue (Q1, 2017) | 75 k |

## Net income (Q1, 2017) | (27.2 m) |

## EBIT (Q1, 2017) | (27.1 m) |

## Market capitalization (17-Aug-2017) | 698.3 m |

## Cash (31-Mar-2017) | 38.2 m |

Revance Therapeutics's current market capitalization is $698.3 m.

USD | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|

## Revenue | 383 k | 300 k | 300 k |

## Revenue growth, % | (22%) | ||

## R&D expense | 47.5 m | 50.4 m | |

## General and administrative expense | 25.1 m | 29.1 m | |

## Operating expense total | 72.6 m | 88.5 m | |

## EBIT | (72.3 m) | (88.2 m) | |

## EBIT margin, % | (24106%) | (29405%) | |

## Interest expense | (1.2 m) | (1.1 m) | |

## Interest income | 231 k | 1.2 m | |

## Net Income | (62.9 m) | (73.5 m) | (89.3 m) |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Revenue | 75 k | 75 k | 75 k | 75 k | 75 k | 75 k | 75 k | 75 k | 75 k |

## R&D expense | 8.1 m | 8.6 m | 9.3 m | 10.3 m | 13 m | 12.4 m | 15.2 m | 10.3 m | 19.4 m |

## General and administrative expense | 6 m | 6.4 m | 5.8 m | 7.5 m | 7 m | 7.5 m | 7.8 m | ||

## Operating expense total | 8.1 m | 8.6 m | 15.3 m | 16.7 m | 18.8 m | 19.8 m | 22.2 m | 17.8 m | 27.2 m |

## EBIT | (12.9 m) | (13.8 m) | (15.2 m) | (16.6 m) | (18.8 m) | (19.7 m) | (24.1 m) | (17.7 m) | (27.1 m) |

## EBIT margin, % | (17189%) | (18433%) | (20233%) | (22117%) | (25024%) | (26325%) | (32112%) | (23631%) | (36117%) |

## Interest expense | (267 k) | (228 k) | (165 k) | (279 k) | (390 k) | (315 k) | (286 k) | (256 k) | (193 k) |

## Interest income | 1 k | 14 k | 27 k | 49 k | 68 k | 310 k | 324 k | 306 k | 311 k |

## Net Income | (16.8 m) | (19.2 m) | (19.9 m) | (24.6 m) | (18 m) | (27.2 m) |

USD | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|

## Cash | 171 m | 201.6 m | 63.5 m |

## Accounts Receivable | 155.5 m | ||

## Inventories | 1.6 m | 1.6 m | 7.2 m |

## Current Assets | 172.7 m | 254 m | 192.7 m |

## PP&E | 19.3 m | 19.7 m | 10.6 m |

## Total Assets | 192.5 m | 275.8 m | 204.4 m |

## Accounts Payable | 3.1 m | 2.7 m | 3.8 m |

## Current Liabilities | 10.2 m | 12 m | 19.6 m |

## Total Liabilities | 27.3 m | ||

## Additional Paid-in Capital | 435.1 m | 585.5 m | 598.6 m |

## Retained Earnings | (258.8 m) | 332.3 m | (421.5 m) |

## Total Equity | 253.3 m | 177.1 m | |

## Financial Leverage | 1.1 x | 1.2 x |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Cash | 203.3 m | 187.5 m | 153.7 m | 96.4 m | 90.5 m | 40.8 m | 52.7 m | 130.5 m | 38.2 m |

## Current Assets | 206.6 m | 190.9 m | 155.7 m | 137.3 m | 143.5 m | 238.5 m | 218.6 m | 208.7 m | 197.5 m |

## PP&E | 16.3 m | 17.4 m | 19.4 m | 19.1 m | 19.3 m | 19.7 m | 17.7 m | 17.4 m | 11.2 m |

## Total Assets | 223.3 m | 208.9 m | 175.7 m | 171.2 m | 165.5 m | 259 m | 237 m | 226.9 m | 209.5 m |

## Accounts Payable | 2.7 m | 2.7 m | 2.1 m | 2.2 m | 2.7 m | 3.3 m | 3 m | 2.9 m | 5.6 m |

## Current Liabilities | 18.8 m | 14.7 m | 6.4 m | 10.2 m | 11.7 m | 12.5 m | 11.9 m | 17.5 m | 24 m |

## Additional Paid-in Capital | 429.1 m | 432.5 m | 437.6 m | 439.8 m | 452.5 m | 588.8 m | 592.4 m | 595.4 m | 627.5 m |

## Retained Earnings | (230.6 m) | (244.6 m) | (274.2 m) | (291 m) | (310.2 m) | (352.2 m) | (376.8 m) | (394.7 m) | (448.7 m) |

## Total Equity | 198.5 m | 187.9 m | 148.8 m | 142.4 m | 236.9 m | 215.8 m | 200.7 m | 178.7 m | |

## Financial Leverage | 1.1 x | 1.1 x | 1.2 x | 1.2 x | 1.1 x | 1.1 x | 1.1 x | 1.2 x |

USD | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|

## Net Income | (62.9 m) | (73.5 m) | (89.3 m) |

## Depreciation and Amortization | 2.1 m | 2 m | 1.4 m |

## Inventories | (999 k) | (192 k) | (5.6 m) |

## Accounts Payable | (3.4 m) | (692 k) | 953 k |

## Cash From Operating Activities | (55.1 m) | (55.7 m) | (59.8 m) |

## Purchases of PP&E | (7 m) | (3.3 m) | (1.7 m) |

## Cash From Investing Activities | (6.9 m) | (56.3 m) | (75.5 m) |

## Cash From Financing Activities | 229.1 m | 142.6 m | (2.6 m) |

## Interest Paid | 1.2 m | 802 k | 676 k |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Net Income | (16.8 m) | (19.2 m) | (19.9 m) | (24.6 m) | (18 m) | (27.2 m) | |||

## Accounts Payable | 2.7 m | 2.7 m | 2.1 m | 2.2 m | 2.7 m | 3.3 m | 3 m | 2.9 m | 5.6 m |

USD | Y, 2017 |
---|---|

## Revenue/Employee | 707.5 |

## Financial Leverage | 1.2 x |